Tramadol News and Research

RSS

New online tool offers opioid prescribing recommendations after surgery

How many prescription pain pills should a patient receive after breast cancer surgery? Or a hernia repair? Or a gallbladder removal?

16 Oct 2017

Managing stress, improving pain coping strategies may minimize need for opioids after surgery

Helping patients to better manage stress and improve coping strategies related to pain may minimize the need for opioids following ankle fracture surgery, according to new research appearing in the July 2017 issue of the Journal of the American Academy of Orthopaedic Surgeons.

6 Jul 2017

Study finds substantial use of opioids among older rheumatoid arthritis patients

A new analysis indicates that the use of opioid pain medications in older US rheumatoid arthritis patients peaked in 2010 and is now declining slightly. By 2014, 41% of rheumatoid arthritis patients were regular opioid users.

21 Jun 2017

Opioid use gradually increases few years after bariatric surgery, study shows

While the proportion of adults with severe obesity using prescription opioids initially declines in the months after bariatric surgery, it increases within a matter of years, eventually surpassing pre-surgery rates of patients using the potentially addictive pain medications, according to new research from a National Institutes of Health -funded multicenter study led by the University of Pittsburgh Graduate School of Public Health.

6 Jun 2017

Researchers report supportive care for cancer patients remains insufficient

Pain relief and other forms of supportive care for cancer patients are insufficient, researchers report at the ESMO ASIA 2016 Congress in Singapore.

7 Dec 2016

Radiocarbon method proves Cameroon’s environment is contaminated with synthetic opioid

Tramadol, a synthetic opioid component of the painkiller tramal, was surprisingly identified in 2013 as a natural product of Sarcocephalus latifolia, a tree found in Cameroon.

31 Oct 2015

FDA accepts sNDA to review Brintellix clinical trial data for treatment of major depressive disorder

Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) announced today the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for review to add clinical data regarding the effect of Brintellix (vortioxetine) on certain aspects of cognitive function in adults with Major Depressive Disorder (MDD) to the current product label.

11 Aug 2015

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai Inc. and Arena Pharmaceuticals, Inc. today announced the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as compared to the twice-daily immediate release formulation approved by the US Food and Drug Administration and marketed as BELVIQ.

13 Apr 2015

AHS provides updated assessment of treatments for acute migraine

The January issue of the American Headache Society journal Headache provides an updated assessment of the best treatments to use when a migraine attack occurs. The assessment will form the basis of new AHS treatment guidelines.

21 Jan 2015

Unmet medication need in neuropathic pain

A systematic review and meta-analysis reveals that current treatments for neuropathic pain achieve only a moderate response in patients.

16 Jan 2015

Opioid tramadol can increase hospitalization risk for hypoglycemia

The opioid pain-reliever tramadol appears to be associated with an increased risk of hospitalization for hypoglycemia, a potentially fatal condition caused by low blood sugar, according to a report published online by JAMA Internal Medicine.

9 Dec 2014

Kids exposed to cooking or tobacco smoke more likely to suffer excessive pain after tonsillectomies

New research presented at this year's Euroanaesthesia meeting in Stockholm shows that children exposed to indoor coal-burning stoves and/or second-hand tobacco smoke are much more likely to suffer postoperative complications and excessive pain after tonsillectomies.

2 Jun 2014

Chemists able to trace narcotics substances, prescription drugs in Swedish wastewater

Chemists at Ume- University in Sweden have been able to trace narcotics substances and prescription drugs in measurements of wastewater from 33 Swedish sewage treatment plants. Cocaine, amphetamine, and methamphetamine, in measurable concentrations, were found in a total of half of the locations.

17 Dec 2013

e-Therapeutics begins ETS6103 phase IIb trial for major depressive disorder

e-Therapeutics plc announces that it has started a randomised double-blind controlled phase IIb trial of ETS6103 in major depressive disorder.

31 Oct 2013

ESTEVE reports positive top line results from E-58425 phase II trial for acute pain

ESTEVE, a pharmaceutical company focused on developing novel therapeutics for pain today announces positive top line results from its recently completed phase II trial, which was designed to evaluate the efficacy and safety of E-58425 in acute pain.

16 Oct 2013

Severe arthritis pain treatments: an interview with Professor Walsh, University of Nottingham and Professor Wood, UCL

Pain is defined by the sufferer’s experience. Pain may be severe because it is intense, frequent or sustained, and because it is distressing. The severity of pain is not simply due to what is going on in the joint, but is also affected by how the body processes the pain signals, and the context in which it is experienced.

31 Jul 2013

Forest Laboratories, Pierre Fabre Laboratories announce that FETZIMA gets FDA approval for MDD

Forest Laboratories, Inc. and Pierre Fabre Laboratories announced today that FETZIMA (levomilnacipran extended-release capsules), a once-daily serotonin and norepinephrine reuptake inhibitor, discovered by Pierre Fabre Laboratories and co-developed by Forest Laboratories, Inc. was approved by the U.S. Food and Drug Administration for the treatment of Major Depressive Disorder in adults.

26 Jul 2013

Drug release of tramadol hydrochloride increases from 1.9 to 7.5 hours by adding Novozymes Biopharma’s Hyasis®

Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.

22 Jul 2013

Eisai submits BELVIQ NDS with Health Canada

Arena Pharmaceuticals, Inc. announced today that Eisai Limited (based in Mississauga, Ontario), a subsidiary of Eisai Inc., has submitted a New Drug Submission for BELVIQ (lorcaserin HCl) with Health Canada.

26 Jun 2013

Teva to present abstracts on AZILECT at MDS meeting

Teva Pharmaceutical Industries Ltd. announced today that a number of abstracts will be presented during the 17th Annual International Congress of Parkinson's Disease and Movement Disorders in Sydney, Australia, June 16-20, 2013, also known as the Movement Disorders Society.

15 Jun 2013